timothy sykes logo
SPRC Stock Draws Traders With Psychedelic IP And Quantum Edge Thumbnail
G Google News

SPRC Stock Draws Traders With Psychedelic IP And Quantum Edge

ELLIS HOBBS•UPDATED OCT. 15, 2026, 7:48 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

SciSparc Ltd. stocks have been trading up by 36.09 percent amid heightened investor optimism from recent impactful company news.

Key Takeaways

  • SciSparc’s NeuroThera unit filed three new U.S. patent applications pairing its PEA technology with LSD, ketamine and ibogaine for depression, PTSD, pain and substance use disorders.
  • Through NeuroThera Labs and partner Clearmind Medicine, SciSparc expanded its U.S. IP around psychedelic–N‑acylethanolamine combinations, including proprietary palmitoylethanolamide, targeting multiple CNS and pain indications.
  • NeuroThera’s CliniQuantum arm benchmarked a GPU‑accelerated quantum-simulation platform that screened billions of three‑gene combinations from real‑world data with ~16.8x speedup versus CPU-only setups.
  • The CliniQuantum test validates computational efficiency for SciSparc’s approach, but traders still lack clear visibility on clinical outcomes or near-term revenue impact.

Candlestick Chart

Live Update At 07:47:53 EDT: On Thursday, October 15, 2026 SciSparc Ltd. stock [NASDAQ: SPRC] is trending up by 36.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SPRC has been trading like a classic low-float biotech rollercoaster. Over the last few weeks, SciSparc Ltd. slid from the mid‑$5s toward the low‑$4s, with recent daily closes stepping down from about $5.21 to $3.63. For traders, that’s a meaningful pullback after a prior run, showing fading momentum and profit-taking.

On intraday 5‑minute charts, SPRC has printed wide ranges, with premarket spikes from the low‑$4s to above $5, then sharp reversals. That kind of range tells active traders the stock is highly sensitive to headlines and order flow, not steady fundamentals.

More Breaking News

Fundamentally, SciSparc reported about $856,000 in revenue and trades around 3.0x price‑to‑sales, which is typical for a tiny, story-driven biotech. Book value per share is roughly $7.30, while SPRC trades below that level, implying the market is discounting its asset base and long path to commercialization. The balance sheet shows about $4.6M in cash against total liabilities near $2.5M, giving SciSparc some runway but not deep pockets. Return on capital is sharply negative, reminding traders this is an early-stage R&D play where dilution and volatility are part of the game.

Why Traders Are Watching SPRC Right Now

SPRC is back on radar because SciSparc Ltd. just stacked two key story pillars: psychedelic IP expansion and a flashy quantum‑simulation milestone.

First, the psychedelic angle. Through its majority-owned NeuroThera unit, SciSparc announced three new U.S. patent applications that combine its palmitoylethanolamide (PEA) technology with LSD, ketamine and ibogaine. These are some of the highest‑profile psychedelic compounds in development today. Target indications include depression, PTSD, pain and substance use disorders — huge markets that keep drawing speculative biotech trading.

On top of that, SciSparc, via NeuroThera Labs and partner Clearmind Medicine, added another trio of U.S. patent applications. These cover combinations of LSD, ketamine and ibogaine with N‑acylethanolamines, again including its proprietary palmitoylethanolamide, aimed at central nervous system and pain conditions. For SPRC, more patents mean a wider moat if any of these formulations advance into meaningful clinical data or partnering talks.

Then comes the tech story. NeuroThera’s subsidiary CliniQuantum benchmarked a GPU‑accelerated quantum‑simulation platform that analyzed billions of potential three‑gene combinations from real‑world clinical data, running on an S&P 500 company’s cloud-based quantum architecture. The roughly 16.8x speedup versus CPU‑only computing tells traders that SciSparc is serious about using advanced computation to compress early discovery timelines.

None of this guarantees revenue, but it gives SPRC a narrative: emerging psychedelic IP backed by cutting‑edge data science. That combination often fuels short bursts of momentum when volume rushes in.

Conclusion

For active traders, SPRC is not a sleepy value play; it’s a volatile story stock built on patents, platforms and possibilities. SciSparc Ltd. is broadening its psychedelic IP footprint on two fronts — internally via NeuroThera and externally with Clearmind Medicine — while CliniQuantum pushes into quantum‑style simulation to speed up genomic analysis. The financials show a tiny revenue base, negative returns and a modest cash cushion, so the SciSparc thesis lives and dies on future execution, not current earnings.

That’s exactly why disciplined traders treat SPRC as a trading vehicle, not a long-term guarantee. The stock trades below book value even as SciSparc talks up advanced IP, which can create sharp squeezes when sentiment swings from doubt to hope and back again. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” The recent downtrend from the $5s into the $3s warns anyone chasing bounces to size small and respect risk.

Tim Sykes has hammered this mindset for years: “Patterns repeat, but you never know how far they go, so you focus on the pattern and your risk, NOT your hopes.” For SPRC, the pattern is clear — headline-driven spikes, deep pullbacks and a pipeline full of early-stage shots on goal. Use the SciSparc story for education and research, track the price action, and let the chart — not the hype — dictate every trading decision.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”